US-based Locus Biosciences recently reported positive pharmacokinetic and safety data from the first part of the ongoing Phase 2 trial of...

For years, Dr. Yan Zhang at the University of Michigan wondered why scientists were struggling to adapt certain type I CRISPR systems for gene editing...

Locus Biosciences announced on Wednesday that it successfully completed the world's first clinical trial using a CRISPR-enhanced bacteriophage...

In a world's first, Locus Biosciences has enrolled the first patients in a clinical trial using bacteriophage boosted with CRISPR to precision-kill...